Other languages Edesa Biotech, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-08 pm EDT			5-day change	1st Jan Change
4.55 ^USD	+0.66%		+2.19%	-0.44%

Mar. 05	Top Premarket Gainers	MT
Feb. 09	Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Top Premarket Gainers	Mar. 05
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 09
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 15
Top Premarket Decliners	Dec. 13
Top Premarket Gainers	Nov. 22
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	Nov. 20
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	23-10-25
Top Premarket Decliners	23-10-13
Sector Update: Health Care Stocks Decline in Late Afternoon	23-10-12
Sector Update: Health Care	23-10-12
Top Midday Gainers	23-10-12
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	23-10-12
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	23-10-10
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate	23-09-28
Edesa Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-09
Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens	23-06-28
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-11
Edesa Biotech, Inc. to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting	23-03-16
Edesa Biotech, US FDA Agree on EB05 Phase 3 Trial's Primary Endpoint, Population	23-03-15
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study	23-03-15

No results for this search